申请人:The Cleveland Clinic Foundation
公开号:US10117879B2
公开(公告)日:2018-11-06
Provided herein are compositions, systems, and methods for treating a disease, such as kidney and/or cardiovascular disease, with an agent that reduces the production of trimethylamine (TMA) or trimethylamine-n-oxide (TMAO) in a subject. In certain embodiments, the agent is: i) 3,3-dimethyl-1-butanol (DMB) or a DMB derivative or related compound, ii) acetylsalicylic acid or derivative thereof (e.g., with an enteric coating for delivery to the colon and/or cecum); iii) a flavin monooxygenase 3 (FMO3) inhibitor; iv) a gut TMA lyase inhibitor; v) an antibiotic or antimicrobial; vi) a probiotic or prebiotic; vii) an antiplatelet agent; or viii) a TMA and/or TMAO sequestering agent.
本文提供的组合物、系统和方法用于使用可减少受试者体内三甲胺(TMA)或三甲胺氧化物(TMAO)产生的制剂治疗疾病,如肾脏和/或心血管疾病。在某些实施方案中,药剂是:i) 3,3-二甲基-1-丁醇(DMB)或 DMB 衍生物或相关化合物,ii) 乙酰水杨酸或其衍生物(例如、iii) 黄素单加氧酶 3 (FMO3) 抑制剂;iv) 肠道 TMA 裂解酶抑制剂;v) 抗生素或抗菌剂;vi) 益生菌或益生元;vii) 抗血小板剂;或 viii) TMA 和/或 TMAO 封闭剂。